On 22 January, 22nd Century Group, Inc. (NYSEMKT:XXII) announced that its wholly-owned subsidiary, NASCO Products, LLC, a federally licensed tobacco product manufacturer and participating member of the tobacco Master Settlement Agreement (MSA), made its first shipment of Smoker Friendly private label cigarettes. On Friday shares of 22nd Century Group, Inc. (NYSEMKT:XXII) closed at $1.17.
On 28 January, Ericsson (NASDAQ:ERIC) reported non-IFRS earnings per share (excluding restructuring) of SEK 1.71 (23 cents) in the fourth quarter of 2014. In the fourth quarter of 2014, revenues rose 1% year over year to SEK 68 billion ($9157.7 million). However, it missed the Zacks Consensus Estimate of $9,551 million. For the full year, Ericsson reported revenues of SEK 228 billion ($33.3 billion), which remained flat on a year-over-year basis. Ericsson (NASDAQ:ERIC) in last trading activity moved down -1.86% to close at $12.13. Company weekly performance is -1.54% while its quarterly performance stands at 5.02%. Ericsson (NASDAQ:ERIC) is -8.66% away from its 52 week high.
Saul Centers Inc. (NYSE:BFS) insider Christopher Netter sold 2,001 shares of the stock in a transaction dated Wednesday, January 7th. The shares were sold at an average price of $58.21, for a total transaction of $116,478.21. On last trading day Saul Centers Inc. (NYSE:BFS) decreased -5.32% to close at $57.09. Its volatility for the week is 2.72% while volatility for the month is 2.12%. BFS’s sales growth for past 5 years was 4.30% and its EPS growth for past 5 years was -17.30%. Saul Centers Inc. (NYSE:BFS) monthly performance is -1.11%.
On 21 January, CryoLife Inc. (NYSE:CRY) announced that its Founder and Executive Chairman, Steven G. Anderson, will receive a 2015 Georgia Bio Industry Growth Award. Mr. Anderson is being honored for his dedication to the implantable medical device industry in the state of Georgia. CryoLife Inc. (NYSE:CRY) has 9.40% insider ownership while its institutional ownership stands at 59.80%. In last trading activity company’s stock closed at $11.26.
On 29 January, Biogen Idec Inc. (NASDAQ:BIIB) Fondazione Telethon and Ospedale San Raffaele have entered into a worldwide collaboration to jointly develop gene therapies for the treatment of both hemophilia A and B. On Friday shares of Biogen Idec Inc. (NASDAQ:BIIB) closed at $389.16. Company’s sales growth for last 5 years was 11.10% and EPS growth for next 5 years is recorded as 22.62%.